1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes after transplant in relapsed/refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia patients achieving remissions after menin inhibition: SNDX-5613 (revumenib) Ph1 experience
    Meeting Abstract

    Issa, G. C.; Cuglievan, B.; Stein, E.; Arellano, M. L.; Žucenka, A.; Khera, N.; Stone, R. M.; Thirman, M. J.; DiPersio, J. F.; Karras, N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Preliminary data from the phase I/II study of TP-3654, a selective oral PIM1 kinase inhibitor, in patients with myelofibrosis previously treated with or ineligible for JAK inhibitor therapy
    Meeting Abstract

    El Chaer, F.; McCloskey, J.; Rein, L. A. M.; Brown, R. A.; Green, S. D.; Pu, J. J.; Shirane, S.; Shimoda, K.; Ichii, M.; Yuda, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia
    Meeting Abstract

    Bewersdorf, J. P.; Patel, K. K.; Goshua, G.; Shallis, R. M.; Podoltsev, N. A.; Stahl, M. F.; Stempel, J. M.; Stein, E.; Huntington, S. F.; Zeidan, A. M.
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of add-on parsaclisib to ruxolitinib therapy in myelofibrosis patients with suboptimal response to ruxolitinib: Final results from a phase 2 study
    Meeting Abstract

    Yacoub, A.; Borate, U.; Rampal, R. K.; Ali, H.; Wang, E.; Gerds, A. T.; Hobbs, G. S.; Kremyanskaya, M.; Winton, E.; O'Connell, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Variability in pattern of mutational signatures in multiple myeloma as a function of racial origin
    Meeting Abstract

    Blaney, P.; Boyle, E. M.; Maclachlan, K. H.; Williams, L. S.; Gagler, D.; Sudha, P.; Poos, A. M.; Wang, Y.; Ghamlouch, H.; Tenenbaum, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Imetelstat-mediated alterations in lipid metabolism to induce ferroptosis as therapeutic strategy for acute myeloid leukemia
    Meeting Abstract

    Bruedigam, C.; Porter, A. H.; Song, A.; in de Wei, G. V.; Stoll, T.; Straube, J.; Cooper, L. T.; Cheng, G. D.; Kahl, V. F. S.; Sobinoff, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Association of metabolic tumor volume (MTV) and clinical outcomes in second-line (2L) relapsed/refractory (R/R) large B-cell lymphoma (LBCL) following axicabtagene ciloleucel (axi-cel) versus standard-of-care (soc) therapy in ZUMA-7
    Meeting Abstract

    Locke, F. L.; Oluwole, O. O.; Kuruvilla, J.; Thieblemont, C.; Morschhauser, F.; Salles, G.; Rowe, S. P.; Vardhanabhuti, S.; Filosto, S.; To, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of the PI3Kδ inhibitor zandelisib in combination with the BTK inhibitor zanubrutinib in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or mantle cell lymphoma (MCL)
    Meeting Abstract

    Soumerai, J. D.; Diefenbach, C. S.; Samaniego, F.; Kumar, A.; Tsai, M. L.; Asch, A. S.; Jagadeesh, D.; Kenkre, V. P.; Lossos, I. S.; Salman, H.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • SARS-CoV-2 vaccinations do not lead to progression of monoclonal gammopathy of undetermined significance: Results from the population-based iStopMM screening study
    Meeting Abstract

    Palmason, R.; Eythorsson, E.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Ekberg, S.; Crowther, M.; Reed, E. R.; Oskarsson, J. Þ.; Sigurdardottir, G. A.; Aspelund, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Predictors and outcomes of immune effector cell associated neurotoxicity syndrome in patients receiving chimeric antigen receptor T-cell therapy for aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Patel, V.; Bhaskar, S.; Schuster, S. J.; Nastoupil, L. J.; Perales, M. A.; Shouval, R.; McGuirk, J. P.; Maziarz, R. T.; Chen, A.; Bachanova, V.; more...
    Blood (2022)

    Fulltext@MSK | Save